aetherAI vs Artera
aetherAI's homepage lists a slide management and viewing system with annotation and a fully automated scanning solution built with Techman Robot and Hamamatsu Photonics. A hospital pathology department going digital fits that offer. The company is based in Taipei and was founded in October 2015.
Artera reaches a different department. Its homepage sells the ArteraAI Prostate Test and the ArteraAI Breast Cancer Test, which a clinician orders and Artera's CLIA lab runs on existing H&E slides, with results within 1 to 2 days of specimen receipt. The FDA De Novo (DEN240068, July 2025) covers the ArteraAI Prostate software device for males 55 or older, and K254115 (May 2026) covers ArteraAI Breast software for early-stage HR+/HER2-negative invasive breast cancer. Artera lists SOC 2 Type II and HIPAA compliance and says the test is fully reimbursed for Medicare patients, a vendor claim.
Pathology · Reviewed November 2, 2026
aetherAI
by aetherAI · founded 2015
FDA-cleared slide viewer for hospital pathology labs. Bone marrow and colon polyp AI modules are TFDA approved in Taiwan.
Artera
by Artera
AI risk scores from H&E slides for prostate and breast cancer, run by a CLIA lab. ArteraAI Prostate software is FDA De Novo authorized.
When to pick each one
aetherAI
- Fits a hospital pathology department going digital
- Scanning solution built with Techman Robot and Hamamatsu
Artera
- Prostate De Novo DEN240068, breast 510(k) K254115
- SOC 2 Type II and HIPAA on homepage
Score
Each row shows points earned of points available under the published rubric.
aetherAI
51of 100
Artera
65of 100
| Dimension | aetherAI | Artera | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 10 / 10 | -10 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 14.7 / 21 | 14.7 / 21 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 7.8 / 7.8 | -7.8 |
| Funding & adoption signal | 3 / 12 | 3 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
aetherAI
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Artera
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
aetherAI
FDA decisions
K233126 (opens in new tab)510(k)2024-05-30
aetherSlide
Peer-reviewed
2 PubMed records name aetherAI.
Artera
FDA decisions
K254115 (opens in new tab)510(k)2026-05-04
ArteraAI Breast
DEN240068 (opens in new tab)De Novo2025-07-31
ArteraAI Prostate
Peer-reviewed
4 PubMed records name Artera.
- Multi-institutional Patient-level Comparison of Decipher Genomic Classifier and Artera Multimodal Artificial Intelligence (MMAI) in Prostate Cancer. (opens in new tab)
- External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol. (opens in new tab)
- A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | aetherAI | Artera |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2015 | n/a |
| HQ | TW | US |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.